Mark J. Alles
Chairman and Chief Executive Officer
Mark J. Alles serves as Celgene Corporation’s Chairman and Chief Executive Officer. He assumed the role of Chief Executive Officer and joined the Celgene Board of Directors on March 1, 2016. The role of Chairman was added on February 6, 2018.
Mr. Alles served as President and Chief Operating Officer from August 2014 until February 2016, Executive Vice President and Global Head of Hematology and Oncology from December 2012 until July 2014, and was also Celgene’s Chief Commercial Officer. Mr. Alles joined Celgene in April 2004 and was Vice President, Global Hematology Marketing until March 2009 when he was promoted to President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Before joining Celgene, he was Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals and served in other senior commercial management roles at Aventis (Rhône-Poulenc Rorer) from 1993-2004.
After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles began his thirty-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He is a member of the Board of Directors of the Pharmaceutical Manufacturers of America (PhRMA), the European Federation of the Pharmaceutical Industries and Associations (EFPIA), and serves on the Board of Gilda’s Club NYC, a non-profit organization dedicated to helping families of people living with cancer.
Richard W. Barker, D.Phil., OBE
Director, Centre for Accelerating Medical Innovations
Richard W. Barker, D.Phil., OBE, was elected to the Celgene Board of Directors in January 2012 and is a member of the Audit Committee.
Dr. Barker was formerly Director General of the Association of the British Pharmaceutical Industry (ABPI), a pharmaceutical industry trade association in the United Kingdom, from 2004 to 2011, and served on the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and as a Council Member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Dr. Barker is currently Director of the Centre for the Advancement of Medical Innovations (CASMI), Director of Precision Medicine PLC, a UK government research entity, Chairman of the Health Innovation Network of South London, UK, Chairman of International Health Partners, a UK charity providing donated medicines to crisis situations, and Chairman of Image Analysis Group, a company applying advanced algorithmic analysis to medical images.
Former President and Chief Executive Officer, Juno Therapeutics, Inc.
Hans Bishop was elected to the Celgene Board of Directors in April 2018.
Mr. Bishop co-founded Juno Therapeutics in 2013 and served as President and CEO until Juno was acquired by Celgene in March 2018. He served as an Executive in Residence at Warburg Pincus, a global private equity firm with significant investment experience in the pharmaceutical and healthcare industries. Prior to this, he acted as Executive Vice President and Chief Operating Officer for Dendreon, a Seattle-based biotechnology company that develops immunotherapy products used in cancer treatment. He has served as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals. Mr. Bishop previously held various positions at Glaxo Wellcome and SmithKlineBeecham. Mr. Bishop earned a B.S. in chemistry from Brunel University in London.
Michael W. Bonney
Chief Executive Officer and Chairman of the Board, Kaleido Biosciences
Michael W. Bonney was elected to the Celgene Board of Directors in April 2015. Mr. Bonney is a member of the Executive Committee and the Nominating, Governance and Compliance Committee.
Mr. Bonney is currently the CEO and Chairman of the Board of Kaleido Biosciences, Inc. From January to July 2016, Mr. Bonney was a Partner of Third Rock Ventures, LLC. Prior thereto, Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 until his retirement in 2014. From 2002 to 2003, Mr. Bonney served as Cubist’s President and Chief Operating Officer, and from 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc., including Vice President, Sales and Marketing from 1999 to 2001. Prior to joining Biogen, Mr. Bonney held various positions of increasing responsibility in sales, marketing and strategic planning at Zeneca Pharmaceuticals. Mr. Bonney is Chairman of the Board of Directors of Alnylam Pharmaceuticals, Inc. He is also a Trustee of the Tekla complex of life sciences and healthcare dedicated funds. Mr. Bonney received a B.A. in Economics from Bates College and now Chairs its Board of Trustees.
Mr. Bonney was a Director of NPS Pharmaceuticals, Inc. from 2005 until its sale to Shire plc in February 2015, where he was a member of the audit and compensation committees and chaired the governance committee. He was a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) from 2009 – 2014 and the Biotechnology Industry Organization (BIO), a non-profit biotechnology trade organization, from 2004 – 2009. Mr. Bonney received a B.A. in Economics from Bates College.
Michael D. Casey
Former President and Chief Executive Officer, Matrix Pharmaceutical, Inc.
Michael D. Casey was elected to the Celgene Board of Directors in August 2002 and has been the Lead Independent Director since June 2007. Mr. Casey is the Chairman of the Nominating, Governance and Compliance Committee, a member of the Executive Committee, and a member of the Compensation and Development Committee.
From September 1997 to February 2002, Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the retail and specialty products division of Schein Pharmaceutical, Inc. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a director of Abaxis Inc.
Carrie S. Cox
Chairman of the Board of Directors and Chief Executive Officer, Humacyte, Inc.
Carrie S. Cox was elected to the Celgene Board of Directors in December 2009 and is a member of the Compensation and Development Committee.
Ms. Cox currently serves as the Chairman of the Board of Directors and Chief Executive Officer of Humacyte, Inc., a privately-held regenerative medicine company primarily focused on developing novel human tissue-based investigational products for applications in regenerative medicine and vascular surgery. Ms. Cox served as Executive Vice President of Schering-Plough and President of Schering-Plough’s Global Pharmaceutical Business until 2009 when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s pharmaceutical business until its merger with Pfizer Inc. in 2003. Ms. Cox is a member of the Board of Directors of Texas Instruments and Cardinal Health, Inc. Ms. Cox is a graduate of the Massachusetts College of Pharmacy.
Michael A. Friedman, M.D.
Emeritus Chief Executive Officer, City of Hope
Michael A. Friedman, M.D., was elected to the Celgene Board of Directors in February 2011 and is a member of the Nominating, Governance and Compliance Committee.
Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration (FDA), later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has served on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Smith & Nephew plc. and Intuitive Surgical, Inc. He is also a member of the Board of Trustees of Tulane University.
Julia A. Haller, M.D.
Ophthalmologist-in-Chief, Wills Eye Hospital
Julia Haller, M.D., was elected to the Celgene Board of Directors in October 2015 and is a member of the Audit Committee.
Dr. Haller is Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia, where she holds the William Tasman, M.D. Endowed Chair. She serves as Professor and Chair of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals, and is Co-Director of the Wills Vision Research Center at Jefferson. In 1986, Dr. Haller served as the first female Chief Resident at the Wilmer Eye Institute at Johns Hopkins and later joined the Johns Hopkins faculty. She was named the inaugural Katharine Graham Professor of Ophthalmology in 2002, and the inaugural Robert Bond Welch, M.D. Professor of Ophthalmology in 2006. In 2007, Dr. Haller assumed leadership of Wills Eye Hospital. She received her A.B. from Princeton University magna cum laude and her M.D. from Harvard Medical School.
Patricia Hemingway Hall
Former Chief Executive Officer, Health Care Service Corporation (HCSC)
Patricia “Pat” Hemingway Hall was elected to the Celgene Board of Directors in April 2018 and is a member of the Audit Committee.
Ms. Hemingway Hall has more than 30 years of experience with a focus on the US health insurance market. Ms. Hemingway Hall retired as CEO of Health Care Service Corporation (HCSC), the nation’s largest mutual health insurance company, which operates as Blue Cross and Blue Shield in Illinois, Montana, New Mexico, Oklahoma and Texas, in 2015. Previously, Ms. Hemingway Hall served as President and Chief Operating Officer of HCSC and as President of Blue Cross and Blue Shield of Texas (BCBSTX). Prior to joining HCSC in 1993, she held positions at A. Foster Higgins, Aetna/Partners Health Plans, VHA and Blue Cross and Blue Shield of Florida. Ms. Hemingway Hall currently serves on the boards of directors of Manpower Group and Cardinal Health. She earned a Master’s in Public Health, health planning and administration from the University of Michigan and a Bachelor of Science in nursing from Michigan State University.
Gilla Kaplan, Ph.D.
Director of the Global Health Program for Tuberculosis, Bill and Melinda Gates Foundation
Gilla Kaplan, Ph.D., was elected to the Celgene Board of Directors in April 1998.
Dr. Kaplan was appointed Director of the Global Health Program, Tuberculosis, at the Bill and Melinda Gates Foundation in January 2014. She previously served as Senior Advisor to the Global Health Program, Tuberculosis and member of the International Scientific Advisory Committee for the Global Health Program of the Bill and Melinda Gates Foundation. Dr. Kaplan was head of the Laboratory of Mycobacterial Immunity and Pathogenesis at The Public Health Research Institute Center at the New Jersey Medical School, Newark, New Jersey, where she was appointed full Member in 2002 and Assistant Director in 2006. Dr. Kaplan also was previously appointed, in 2005, Professor of Medicine at the University of Medicine and Dentistry of New Jersey. Prior to that, Dr. Kaplan was an immunologist in the Laboratory at Cellular Physiology and Immunology at The Rockefeller University in New York where she was an Associate Professor.
James J. Loughlin
Retired Partner KPMG, LLP
James J. Loughlin was elected to the Celgene Board of Directors in January 2007. Mr. Loughlin is Chairman of the Audit Committee and a member of the Compensation and Development Committee.
Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG LLP (KPMG), and a five-year term as member of the Board of Directors of KPMG. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. Mr. Loughlin serves as a member of the Board of Directors of Edge Therapeutics, Inc.
Ernest Mario, Ph.D.
Former Deputy Chairman and Chief Executive, Glaxo Holdings plc.
Ernest Mario, Ph.D . was elected to the Celgene Board of Directors in August 2007. Dr. Mario is Chairman of the Compensation and Development Committee, a member of the Nominating, Governance and Compliance Committee, and a member of the Executive Committee.
Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario currently is the Chairman of Capnia, Inc., a privately-held specialty pharmaceutical company in Palo Alto, California. Dr. Mario serves as a member of the Board of Directors for Boston Scientific Corporation, Chimerix Inc., Kindred Biosciences Inc., XenoPort Inc. and Tonix Pharmaceuticals Holding Corp. He is Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. In 2007, Dr. Mario was awarded the Remington Medal by the American Pharmacists Association, pharmacy’s highest honor.
John H. Weiland
Former President and Chief Operating Officer, C.R. Bard
John Weiland was elected to the Celgene Board of Directors in February 2018 and is a member of the Audit Committee.
Mr. Weiland was President and Chief Operating Officer of C. R. Bard, Inc. from 1996 until his retirement in 2017 when C.R. Bard was acquired by Becton Dickinson. He was elected to Bard’s Board of Directors in 2005 and became Vice Chairman of the Board in 2016. Prior to becoming President and COO, he held the position of Group President. Prior to Bard, Mr. Weiland held the position of Senior Vice President North America Group for Dentsply International. Mr. Weiland started his career at Baxter/American Hospital Supply Corporation in 1977. He rose through numerous managerial positions to become Vice President and General Manager of the Scientific Products Biomedical Division. In 1989, he became President and Chief Executive Officer of Pharmacia Diagnostics, a division of Pharmacia AB Uppsala Sweden. In addition to his professional activities, John is actively involved in civic affairs. In 2012, John was the recipient of the distinguished Horatio Alger Award. He is a member of the Board of Directors of West Pharmaceutical Services, Inc. and the Horatio Alger Association. Mr. Weiland graduated from DeSales University with a B.S. degree and earned an M.B.A. degree from New York University.